resiquimod has been researched along with Infections, Chlamydia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Cocco, MJ; de la Maza, LM; le Bon, C; Pal, S; Tifrea, DF; Zoonens, M | 1 |
Aldon, Y; Blakney, AK; Christensen, D; Follmann, F; McKay, PF; Shattock, RJ; Yus, BI | 1 |
2 other study(ies) available for resiquimod and Infections, Chlamydia
Article | Year |
---|---|
Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Vaccines; Chlamydia Infections; Chlamydia muridarum; Imidazoles; Mice; Mice, Inbred BALB C; Oligodeoxyribonucleotides | 2020 |
Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA.
Topics: Adjuvants, Immunologic; Animals; Bacterial Vaccines; Cations; Chlamydia Infections; Chlamydia trachomatis; Female; Heterocyclic Compounds, 3-Ring; Imidazoles; Immunity, Cellular; Immunity, Humoral; Immunogenicity, Vaccine; Immunologic Factors; Liposomes; Mice; Mice, Inbred BALB C; RNA; Stearic Acids; Transfection | 2019 |